CN1268748C - 病毒疫苗 - Google Patents

病毒疫苗 Download PDF

Info

Publication number
CN1268748C
CN1268748C CNB998165611A CN99816561A CN1268748C CN 1268748 C CN1268748 C CN 1268748C CN B998165611 A CNB998165611 A CN B998165611A CN 99816561 A CN99816561 A CN 99816561A CN 1268748 C CN1268748 C CN 1268748C
Authority
CN
China
Prior art keywords
mixture
sequence
dna
ring
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998165611A
Other languages
English (en)
Chinese (zh)
Other versions
CN1348496A (zh
Inventor
M·施雷贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strathmann GmbH and Co KG
Original Assignee
Strathmann GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strathmann GmbH and Co KG filed Critical Strathmann GmbH and Co KG
Publication of CN1348496A publication Critical patent/CN1348496A/zh
Application granted granted Critical
Publication of CN1268748C publication Critical patent/CN1268748C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB998165611A 1999-02-12 1999-12-03 病毒疫苗 Expired - Fee Related CN1268748C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19907485A DE19907485B4 (de) 1999-02-12 1999-02-12 Virus-Vakzine
DE19907485.2 1999-02-12

Publications (2)

Publication Number Publication Date
CN1348496A CN1348496A (zh) 2002-05-08
CN1268748C true CN1268748C (zh) 2006-08-09

Family

ID=7898389

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998165611A Expired - Fee Related CN1268748C (zh) 1999-02-12 1999-12-03 病毒疫苗

Country Status (12)

Country Link
US (1) US20060222665A1 (enExample)
EP (1) EP1149167B1 (enExample)
JP (1) JP2002536418A (enExample)
CN (1) CN1268748C (enExample)
AT (1) ATE260978T1 (enExample)
AU (1) AU1976100A (enExample)
DE (2) DE19907485B4 (enExample)
DK (1) DK1149167T3 (enExample)
ES (1) ES2216619T3 (enExample)
PT (1) PT1149167E (enExample)
WO (1) WO2000047223A2 (enExample)
ZA (1) ZA200106155B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118874B2 (en) * 1998-10-09 2006-10-10 Variation Biotechnologies Inc. Immunogenic formulation and process for preparation thereof
EP1311278A4 (en) * 2000-08-07 2005-01-05 Sloan Kettering Institutefor C METHOD AND IMMUNIZATION COMPOSITION USING MIXED POOLS OF NUCLEIC ACIDS OR MUTED PEPTIDES
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
CN101591379B (zh) * 2008-05-27 2017-01-18 中国疾病预防控制中心性病艾滋病预防控制中心 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
CN103865945A (zh) * 2010-02-10 2014-06-18 中国人民解放军军事医学科学院放射与辐射医学研究所 Tat核心肽段在制备高效、可溶性表达的外源蛋白中的应用
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US10245313B2 (en) * 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity
WO2016187151A1 (en) * 2015-05-18 2016-11-24 Calimmune, Inc. Methods of discriminating between hiv-1 and lentiviral vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions
FR2677363A1 (fr) * 1991-06-07 1992-12-11 Pasteur Institut Compositions a base de peptides multiepitopiques, leur procede d'obtention et leurs applications, notamment en tant que vaccins.
WO1994022917A1 (en) * 1993-04-05 1994-10-13 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
AU6829494A (en) * 1993-08-02 1995-02-28 Chiron Corporation Recombinant constructs using replacement sequences in hypervariable regions
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Also Published As

Publication number Publication date
ES2216619T3 (es) 2004-10-16
DE59908783D1 (de) 2004-04-08
JP2002536418A (ja) 2002-10-29
AU1976100A (en) 2000-08-29
EP1149167A2 (de) 2001-10-31
US20060222665A1 (en) 2006-10-05
PT1149167E (pt) 2004-07-30
EP1149167B1 (de) 2004-03-03
ZA200106155B (en) 2002-08-05
DK1149167T3 (da) 2004-07-12
DE19907485B4 (de) 2008-01-17
DE19907485A1 (de) 2000-09-28
WO2000047223A2 (de) 2000-08-17
WO2000047223A3 (de) 2000-11-16
CN1348496A (zh) 2002-05-08
ATE260978T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
Tomasselli et al. Substrate analog inhibition and active site titration of purified recombinant HIV-1 protease
CN1250731C (zh) 正链rna病毒复制子颗粒的包装
CN1171996C (zh) 北美猪生殖和呼吸综合征(prrs)病毒及其用途
CN1268748C (zh) 病毒疫苗
CN1502698A (zh) 用于重组生产抗融合肽的方法
CN1515319A (zh) 细胞毒t淋巴细胞应答的诱导
CN1651457A (zh) Hiv－1 o组(或亚组)逆转录病毒抗原的核苷酸序列
CN1333873A (zh) Hiv－特异的t－细胞诱导
CN1346367A (zh) Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法
CN1900290A (zh) 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
CN112626123A (zh) 重组质粒、重组基因vii型新城疫病毒及其培养方法
CN112980865A (zh) 一种重组类人胶原蛋白工程菌的构建方法
CN1079509A (zh) 人体免疫缺陷病毒抗原
CN1425075A (zh) 差异表达筛选方法
CN101031647A (zh) 在大肠杆菌中制备猪丹毒杆菌表面保护性抗原变体的方法
AU609183B2 (en) Antimalaria vaccines
CN107058390A (zh) 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
CN1084565A (zh) 具有腈水合酶活性的新型蛋白和编码该蛋白的基因
US20240408190A1 (en) Influenza vaccines
CN1809381A (zh) 具有稀有二硫化物结构的hiv－1包膜糖蛋白
CN1136280A (zh) 抗艾滋病分泌型重组bcg疫苗
CN113355288B (zh) 一种治疗covid-19的通用型嵌合抗原受体t细胞的制备方法及应用
KR20200132958A (ko) 불활성화된 ul18 및/또는 ul8을 갖는 신규한 ehv
CN102241763A (zh) 一种鱼类持续激活生长激素受体基因及制备方法和用途
CN1616663A (zh) O型口蹄疫病毒dna疫苗及其制备方法

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee